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Abstract: Hydroxyapatite-based biomaterials are commonly used in surgery to repair bone damage.
However, the introduction of biomaterials into the body can cause metabolic alterations, including
redox imbalance. Because vitamins D3 and K (K1, MK-4, MK-7) have pronounced osteoinductive,
anti-inflammatory, and antioxidant properties, it is suggested that they may reduce the adverse
effects of biomaterials. The aim of this study was to investigate the effects of vitamins D3 and K,
used alone and in combination, on the redox metabolism of human osteoblasts (hFOB 1.19 cell
line) cultured in the presence of hydroxyapatite-based biomaterials (Maxgraft, Cerabone, Apatos,
and Gen-Os). Culturing of the osteoblasts in the presence of hydroxyapatite-based biomaterials
resulted in oxidative stress manifested by increased production of reactive oxygen species and
decrease of glutathione level and glutathione peroxidase activity. Such redox imbalance leads to lipid
peroxidation manifested by an increase of 4-hydroxynonenal level, which is known to influence the
growth of bone cells. Vitamins D3 and K were shown to help maintain redox balance and prevent
lipid peroxidation in osteoblasts cultured with hydroxyapatite-based biomaterials. The strongest
effect was observed for the combination of vitamin D3 and MK-7. Moreover, vitamins promoted
growth of the osteoblasts, manifested by increased DNA biosynthesis. Therefore, it is suggested
that the use of vitamins D3 and K may protect redox balance and support the growth of osteoblasts
affected by hydroxyapatite-based biomaterials.
Keywords: hydroxyapatite-based biomaterials; osteoblast growth; redox balance; vitamins;
lipid peroxidation; 4-hydroxynonenal; oxidative stress
1. Introduction
Hydroxyapatite-based biomaterials possess osteoconductive properties and can also act as
three-dimensional scaffolds to support bone regeneration [1]. However, introducing biomaterials
into the body can lead to metabolic alterations. Namely, interactions between osteoblasts and
biomaterials may interfere with cellular metabolism, including redox balance leading to oxidative
stress [2]. The ingredients released by biomaterials may also take part in this activity [3,4]. Compounds
released from bone substitutes can have adverse effects on the viability and function of osteoblasts,
even in the absence of physical contact [2,5,6]. There is also evidence that the production of
pro-inflammatory cytokines by osteoblasts is increased in the presence of hydroxyapatite [7]. The lack
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of cytocompatibility of bone substitutes can hinder bone regeneration and prolong wound healing [8].
To reduce the cytotoxicity of biomaterials and enhance their desirable bioactivities, they are often
modified by the inclusion of various compounds, including growth factors [9] and antioxidants, e.g.,
N-acetylcysteine [5], or combined with other components, such as matrix-derived proteins [10].
The physiology of bone metabolism is dependent on the synergistic interplay between vitamins
D3 and K [11]. The active form of vitamin D3 is 1,25-dihydroxycholecalciferol (1,25(OH)2D3; calcitriol).
Calcitriol forms a complex with a specific nuclear receptor, commonly known as the vitamin D receptor
(VDR), to control the expression of key bone-related proteins in osteoblasts, including osteocalcin (OC),
and to regulate calcium and phosphate homeostasis [12,13]. The antioxidant and anti-inflammatory
properties of vitamin D3 have been confirmed both in vitro and in vivo. Under pathological conditions,
vitamin D3 has been shown to enhance the level and activity of antioxidant proteins which protect
cellular proteins from oxidative modification. Vitamin D3 activates the Nrf2-Keap1 antioxidant
pathway leading to transcription of antioxidant proteins and has been shown to reduce levels of
advanced glycation end-products in the aortic wall of diabetic rats [14,15]. Administering vitamin
D3 to rats increased the activity of an antioxidant enzyme superoxide dismutase (SOD) in the liver.
Furthermore, a decrease in vitamin D3 levels in the blood serum in obese children was correlated
with a decrease in SOD levels [16–19]. Changes in antioxidant capacity correspond to an increase in
lipid peroxidation [20]. Vitamin D3 also inhibits oxidative stress and endoplasmic reticulum stress in
endothelial cells thereby reducing the risk of cardiovascular disease in humans [21] and preventing
endothelial cell death [22]. In addition, vitamin D3 plays a role in T cell-mediated immunity [23].
The vitamin K family is a group of fat-soluble vitamins that regulate metabolic processes [24].
The two main forms of vitamin K are phylloquinone (K1) and menaquinone (K2), including the
menaquinone-4 (MK-4) and menaquinone-7 (MK-7) homologues. Vitamin K1 is transported to the
liver where it regulates the production of coagulation factors, whereas vitamin K2 is found in many
tissues, including bone, where it regulates the activity of vitamin K-dependent proteins, such as
matrix carboxyglutamic acid (Gla)-protein (MGP) and OC (GLA protein) [25]. Bone metabolism
depends on interaction between vitamins D3 and K2. Vitamin D promotes vitamin K-dependent
protein production while vitamin K activates proteins involved in bone metabolism. Vitamin K acts
as a cofactor in the carboxylation of glutamic acid (Glu) to Gla and the metabolically active form
of OC, which can bind and deposit calcium in the extracellular matrix [11,26]. In vitro, vitamin K2
was shown to promote osteoclast apoptosis in a dose-dependent manner and to suppress osteoblast
apoptosis [27,28]. Moreover, it was found that vitamin K2 increases the number and activity of
osteoclasts [28] and the MK-4 homologue promotes osteoblast differentiation and proliferation of
osteoclasts [29].
Vitamin K participates in blood coagulation, signal transduction processes, and cell
proliferation [30], and has the ability to alter redox balance in cells [31]. In its reduced form, vitamin K
hydroquinone (KH2) protects phospholipid membranes from peroxidation by direct reactive oxygen
species (ROS) uptake [32]. During the vitamin K cycle, hydroquinone is reconstituted with the
participation of vitamin K epoxide reductase complex subunit 1 (VKORC1) [31]. Vitamin K inhibits the
activation of 12-lipoxygenase (12-LOX) to prevent the formation of ROS [33]. The antioxidant actions
of vitamins K1 and K2 (MK-4) protect oligodendrocytes and neurons from oxidative stress caused
by glutathione (GSH) deficiency [34]. Nanomolar concentrations of vitamins K1 and K2 (MK-4)
were also shown to prevent oxidative stress-induced neuronal death [33]. Since oxidative stress is
directly associated with inflammation, vitamin K may reduce oxidative stress by lowering levels of
pro-inflammatory factors [35,36].
There is a growing body of evidence to suggest vitamin K and vitamin D have synergistic effects
on bone metabolism [11,37,38]. The aim of the present study was to investigate the effect of vitamin D3
and K on cellular metabolism and to determine whether vitamins D3, K1, MK-4, and MK-7 could be
potentially used to support bone regeneration alongside hydroxyapatite-based biomaterials. Therefore,
redox balance in osteoblasts cultured in presence of biomaterials was determined. The biomaterials
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characterized by origin—human (Maxgraft), bovine (Cerabone), porcine (Apatos and Gen-Os),
and composition—hydroxyapatite (Maxgraft, Cerabone, Apatos) and hydroxyapatite enriched with
collagen (Gen-Os) were examined.
2. Materials and Methods
2.1. Materials
To evaluate the in vitro effect of vitamin K (K1, MK4, and MK7) and vitamin D3 on osteoblasts’
metabolism cultured with biomaterial cells were cultured on commercial biomaterials of different
origin and chemical composition. Vitamin K1 (Sigma–Aldrich, St. Louis, MO, USA), vitamin
K2 (Menaquinone 4, MK4 (Sigma–Aldrich, St. Louis, MO, USA) and Menaquinone 7, MK7 (was
chemically synthesized by the Pharmaceutical Research Institute, Warsaw, Poland)), and vitamin
D3 (1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (Santa Cruz Biotechnology, USA)), was added to cells.
Four different hydroxyapatites: human origin (Maxgraft, Botiss biomaterials GmgH, Germany),
bovine origin (Cerabone, Botiss Biomaterials GmbH, Germany), porcine origin (Apatos, Tecnoss,
Italy), and porcine hydroxyapatite with preserved collagen (Gen-Os, Tecnoss, Italy) were used
for experiments.
2.2. Cell Cultures and Treatments Used
All experiments were performed using a human fetal osteoblast cell line (hFOB 1.19) obtained from
ATCC (American Type Culture Collection, Menassas, VA, USA). The optimal time to assess metabolic
changes during osteoblast differentiation is about 20 days [39]. During this period, three stages of
osteoblast differentiation can be distinguished: proliferation (until day 4), synthesis of extracellular
matrix (between 12–16 days), and mineralization of the extracellular matrix of the bone (about day
20) [39,40]. Cells were cultured for 20 days at 39 ◦C in 5% CO2 in air in a 1:1 mixture of Ham’s F12
medium and Dulbecco’s modified Eagles’s medium containing 2.5 mmol/L L-Glutamine without
phenol red and supplemented with 0.3 mg/mL G418, 100 U/mL penicillin, 100 µg/mL streptomycin,
and 10% fetal bovine serum (FBS). Culture medium was renewed every 2 days.
For all experiments, osteoblasts were seeded on each of the hydroxyapatite-based biomaterials
(Maxgraft, Cerabone, Apatos, Gen-Os; 100 mg/well) at a density of 1 × 105 cells/well in 6-well
plates. The influence of vitamin D3 and vitamin K on osteoblast growth was investigated by dividing
the cells into several treatment groups: cells treated with vitamin D3, cells treated with vitamin K
(K1, MK-4, or MK-7), and cells treated with combinations of vitamin D3 and K (D3+K1, D3+MK-4,
or D3+MK-7). Controls without any hydroxyapatite were cultured in parallel. Cells were supplemented
with vitamin K1 and K2 (MK-4 and MK-7) at a concentration of 10 µmol/L [29,41] and/or vitamin
D3 at concentration 1 nM in the presence of 10 mmol/L sodium β-glycerophosphate to accelerate the
mineralization process. After 4, 8, 12, 16, and 20 days, cells were collected. Vitamin D3 was used in its
metabolically active form of 1,25(OH)2D3, which has previously been shown to regulate osteoblast
differentiation [42,43]. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric
assay was used to study the effect of vitamin D3 on cells and to determine the optimal concentration
of vitamin D following a procedure previously described in the literature [44]. The concentration of
vitamin K used for the MTT assay did not affect cell viability.
To examine the effects of vitamins D3, K1, K2 (MK-4 and MK-7), and hydroxyapatite on osteoblast
proliferation and differentiation, DNA content as well as alkaline phosphatase (ALP) and OC levels
were determined. Redox status was estimated for each group based on measured ROS, GSH,
and 4-hydroxynonenal (4-HNE) levels.
2.3. Determination of ROS Level
Electron spin resonance (ESR) spectrometer e-scans (Noxygen GmbH/Bruker Biospin
GmbH, Germany) were used to detect total ROS generation using spin probe CMH
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(1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetra-methylpyrrolidine, 200 µmol/L), which selectively
interacts with ROS to form a stable nitroxide CM-radical (carbamoyl radical) with a half-life of
4 h [43]. After 4, 8, 12, 16, and 20 days in culture, the cells were suspended in Krebs HEPES
buffer (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid) (KHB) and the CMH spin probe
was added. Samples were incubated for 30 min at 37 ◦C in a mixture of N2 and 02 of 96:4 (02:N2) and
electron paramagnetic resonance (EPR) was performed on cell lysates using the following acquisition
parameters: field center 1.99 g, microwave power 20 mW, amplitude of modulation 2 G, sweep time
10 s, number of scans 10, range of deviation 60 G.
2.4. Determination of GSH Level
Non-enzymatic antioxidant—glutathione (GSH)—was quantified using capillary electrophoresis
(CE) method of Maeso et al. [45]. Cells were sonicated with a mixture containing acetonitrile/water
(ACN/H2O 62.5:37.5, v/v) and centrifuged at 30,000× g for 10 min. The separation of supernatant
components was performed on a capillary with 47 cm total length (40 cm effective length) and 50 µm
i.d. and was operated at 27 kV with UV detection at 200 ± 10 nm.
2.5. Determination of Glutathione Peroxidase Activity
Glutathione peroxidase (GSH-Px, EC 1.11.1.6) activity was estimated by spectrophotometry using
a microplate reader (Infinite M200, Tecan), according to the method of Paglia and Valentine [46].
Enzyme activity was measured using an indirect method involving two conjugated reactions:
glutathione oxidation reaction (catalyzed by glutathione peroxidase) and glutathione reduction reaction
with simultaneous oxidation of reduced nicotinamide adenine dinucleotide phosphate (NADPH) to
NADP. The cell lysate was combined with a mixture containing 1.5 mM ethylenediaminetetraacetic
acid (EDTA; in 0.2 mol/L Tris-HCl buffer; pH 7.6), 15 mmol/L sodium azide, and 0.72 mmol/L
NADPH in a 96-well plate and incubated for 5 min at 20 ◦C. Then glutathione reductase and 0.1 mL of
10 mmol/L H2O2 in 0.02 mmol/L Tris-HCl buffer (pH 7.6) were added to each sample. Absorbance
was measured at 340 nm for 1 min relative to Tris-HCl buffer. One unit of GSH-Px activity was defined
as the amount of enzyme catalyzing the oxidation of 1 µmol NADPH min−1 at 25 ◦C and pH 7.4.
Enzyme specific activity was expressed as micro-units per mg of protein.
2.6. Determination of Lipid Peroxidation
Lipid peroxidation was estimated based on the level of 4-hydroxynonenal (4-HNE)
as a derivative of O-pentafluorobenzyl-oxime-trimethyl silyl ether (O-PFB-oxime-TMS) [47],
assessed using gas chromatography-mass spectrometry (GC/MS) in selected ion monitoring
mode (SIM), according to a previously described method [48]. Briefly, aldehydes were
derivatized by the addition of O-(2,3,4,5,6-pentafluorobenzyl) hydroxylamine (PFB) in PIPES
buffer (piperazine-N,N′-bis(2-ethanesulfonic acid) in the presence of benzaldehyde-D6 as an
internal standard (IS). The O-PFB-oxime aldehyde derivative was extracted using hexane.
The hexane phase was evaporated under a stream of argon followed by the addition of
N,O-bis(trimethylsilyl)trifluoroacetamide in 1% trimethylchlorosilane to form TMS ether of the
hydroxyaldehyde group. A 1 µl aliquot was injected into the GC-MS. Derivatized aldehyde was
analyzed using a 7000 quadrupole MS/MS (7890A GC, Agilent Technologies, USA) equipped with
a HP-5 ms capillary column (0.25-mm internal diameter, 0.25-µm film thickness, 30-m length).
The column temperature was initially set to 50 ◦C for 1 min, increased at a rate of 10 ◦C/min to
200 ◦C, then at 3 ◦C/min to 220 ◦C, 20 ◦C/min to 310 ◦C, and finally, maintained at 310 ◦C for
5 min. The injector temperature was maintained at 250 ◦C, the transfer line was held constant at
280 ◦C, and the source temperature was set to 230 ◦C. Derivatized aldehyde was detected by selected
ion-monitoring GC/MS using the following ions: m/z 333.0 and 181.0 for 4-HNE-PFB-TMS and m/z
307.0 for nternal standard (IS) derivative.
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2.7. DNA Proliferation Assay
A DNA fluorometric assay for measuring osteoblasts proliferation was used [49]. Briefly,
medium was discarded, and cells were washed with a washing solution (0.8% NaCl, 0.04% KCl,
0.1% ethylenediaminetetraacetic acid EDTA, and 1% NaN3). The plates were then allowed to dry
at room temperature for 10 min, wrapped with parafilm, and frozen at −70 ◦ C until analysis.
After removal from the freezer, 0.01% dodecyl sodium sulfate (SDS) was added, and samples were
incubated at room temperature for 15 min. Cell lysates in the amount of 10 µL were put into a 96-well
plate with H33258 at a concentration of 2 µg/mL. The DNA level was measured under excitation
of 360 nm and emission at 460 nm and calculated from the calibration curve for Calf Thymus DNA
solution. The DNA level was expressed as ng of DNA per mg of protein.
2.8. Determination of ALP Activity
Alkaline phosphatase (ALP) activity was determined fluorometrically using the p-nitrophenyl
phosphate (p-NPP) according to Reference [50] at 405 nm. Briefly, a lysis buffer (10 mmol/L Tris-HCl,
pH 7.5, containing 0.5 mmol/L MgCl2, 0.1% Triton X-100) was added to cells, and after 10 min
incubation on ice, cells were collected in tubes and stored at −70 ◦C until analysis. After thawing,
samples were sonicated and centrifuged at 10,000× g for 15 min at 4 ◦C. Next, glycine buffer
(25 mmol/L, pH 10.4) containing 2 mmol/L MgCl2 and 10 mmol/L p-NPP was added to samples,
and then incubated at 37 ◦C for 25 min. The enzymatic reaction was stopped by the addition of 3 mol/L
NaOH. The activity of ALP was expressed as the amount of enzyme (nmol) that catalyzed the reaction
with substrate per minute per mg of protein.
2.9. Determination of OC Level
The osteocalcin (Gla-OC) concentration was determined in the culture medium. The osteocalcin
level was determined using a commercially available human-specific enzyme-linked immunosorbent
assay (ELISA) kit (Gla-type Osteocalcin (Gla-OC) EIA Kit, TaKaRa, Bio Inc.). The tests were performed
according to the manufacturer’s protocol. The OC level was expressed as ng of osteocalcin per ml of
culture media.
2.10. Statistical Analysis
Data were analyzed using standard statistical analyses, one-way/two-way analysis of variance
(ANOVA) to determine significant differences between different groups. All analyses on cells were
performed on the results obtained from three independent experiments. The results are expressed as
the mean ± standard deviation (SD) for n = 3. p-values less than 0.05 were considered significant.
3. Results
3.1. Biochemical Studies
The results obtained show that the growth of osteoblasts was associated with a gradual increase of
ROS levels, the largest increase being observed between the days 8 and 12 (Figure 1). While vitamin D3
did not affect such changes in ROS levels for cultured osteoblasts, the other vitamins attenuated
continuous increases of ROS. The most prominent reduction of ROS production was observed
in MK-7-treated osteoblasts at day 12 and day 16 (16% and 23%, respectively), whereas ROS
levels observed in the K1-treated osteoblasts decreased by 11–17% and in MK-4-treated osteoblasts,
by 14–15%.
Opposite to the vitamins, the hydroxyapatite-based biomaterials further enhanced production
of ROS by cultured osteoblasts, which was also shown to be significantly reduced by vitamins,
depending on the type of biomaterials and vitamins used (Figure 1b–e). Osteoblasts cultured on
hydroxyapatite in medium containing vitamin D3 with either vitamin K1 or K2 exhibited significantly
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lower ROS production, particularly at day 16 and 20, compared to controls (10–20%) or cells grown on
hydroxyapatite-based biomaterials alone (10–20%).
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Figure 1. Reactive oxygen species (ROS) level in osteoblasts after incubation with hydroxyapatites and
treated with vitamins D3, K1, MK4, and K7 after 8, 12, 16, and 20 days. The results are expressed as the
µM/min/mg of protein and are shown as the mean± SD (n = 5). The values for the control cells and the
treated cells were significantly different according to unpaired Student’s t-test. * Statistically significant
differences versus control, p < 0.05; (a) statistically significant differences versus group hydroxyapatites
(Mx (Maxgraft), Cb (Cerabone), Ap (Apatos), Go (Gen-Os), respectively for graphs (b–e)); p < 0.05.
Levels of the main cytosolic antioxidant, GSH, gradually increased in osteoblast cultures until day
12; however, a decrease was observed at day 20 (Figure 2). The addition of vitamin D3 as well as K1
and K2 to culture medium significantly increased GSH concentrations compared to controls. Vitamin
K1 and K2 had slightly less of an effect than vitamin D3. The largest increases in GSH concentration
were observed between day 8 and 20. Furthermore, the combination of vitamin D3 and vitamin K1 or
K2 resulted in enhanced GSH levels compared to cultures treated with only the vitamin K variants.
Cells cultured with hydroxyapatite (Apatos and Gen-Os), exhibited lower GSH levels (Figure 2b–e);
moreover, the addition of vitamin D3 and a mixture of vitamins D3 and K1 or K2 led to a significant
increase in GSH levels compared to controls. The largest increase was observed between day 8 and day
20 in osteoblast cultures treated with vitamin D3 and K1 or K2 in the presence of Maxgraft (17–58%) or
Cerabone (28–54%).
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Figure 2. Glutathione (GSH) level in osteoblasts after incubation with hydroxyapatites and treated
with vitamins D3, K1, MK4, and MK7 after 8, 12, 16, and 20 days. The results are expressed as the
nmol/mg of protein and are shown as the mean ± SD (n = 5). The values for the control cells and the
treated cells were significantly different according to unpaired Student’s t-test. * Statistically significant
differences versus control, p < 0.05; (a) statistically significant differences versus group hydroxyapatites
(Mx (Maxgraft), Cb (Cerabone), Ap (Apatos), Go (Gen-Os), respectively for graphs (b–e)); p < 0.05.
Observed changes in GSH level were associated with changes in GSH-Px activity since GSH is its
co-substrate. Vitamin D3 as well as MK-4 and MK-7 significantly enhanced the activity of GSH-Px
by approximately 16–13% for vitamin D3 alone between 8 and 20 days and by approximately 14%
for D3+MK-4 and D3+MK-7 on day 8 and day 20, compared to controls (Figure 3a). Therefore,
the combination of D3+MK-4 or D3+MK-7 significantly enhanced GSH-Px activity. The most
effective treatment was D3+MK-7 which resulted in a 28% increase after 16 days. The presence
of hydroxyapatite-based biomaterials, in particular Apatos and Gen-Os, led to a decrease in GSH-Px
activity of approximately 11% (Figure 3b–e). Osteoblasts cultured in the presence of hydroxyapatite but
treated with vitamin D3 were characterized by significantly higher GSH-Px activity (9–12% and 11–19%
for Apatos and Gen-Os, respectively) compared to cells grown only in the presence of hydroxyapatite.
However, a combination of vitamins, D3+MK-4 or D3+MK-7, led to a significant increase in GSH-Px
activity even in the presence of hydroxyapatite. For Apatos, GSH-Px activity was enhanced by
approximately 11–17% and 20% with D3+MK-4 and D3+MK-7 treatment, respectively; for Cerabone,
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approximately 15–24% for D3+MK-4 and 18–24% for D3+MK-7, and for Gen-Os, 7–16% for D3+MK-4,
and 9–19% for D3+MK-7.
Cells 2019, 8, x 8 of 19 
 
for Cerabone, approximately 15–24% for D3+MK-4 and 18–24% for D3+MK-7, and for Gen-Os, 
7–16% for D3+MK-4, and 9–19% for D3+MK-7. 
 
Figure 3. GSH-Px activity in osteoblasts after incubation with hydroxyapatites and treated with 
vitamins D3, K1, MK4, and MK7 after 8, 12, 16, and 20 days. The results are expressed as the mU/mg 
of protein and are shown as the mean ± SD (n = 5). The values for the control cells and the treated cells 
were significantly different according to unpaired Student’s t-test. * Statistically significant 
differences versus control, p < 0.05; a statistically significant differences versus group hydroxyapatites 
(Mx (Maxgraft), Cb (Cerabone), Ap (Apatos), Go (Gen-Os), respectively for graphs (b), (c), (d), (e); p < 
0.05.  
Furthermore, biomaterials and vitamins affected redox balance in cultured osteoblasts by 
modifying lipid metabolism, in the manner similar as observed for ROS levels. Namely, the growth 
of osteoblasts was associated with continuous increase of 4-HNE levels (Figure 4). However, 
different from the lack of influence of vitamin D3 on the ROS change, the most significant effects on 
the 4-HNE production were observed in vitamin D3-treated cultures (Figure 4A), followed by MK-7, 
with a reduction of approximately 12–19%. As was noticed in the case of the change of ROS (Figure 
1), the presence of hydroxyapatite biomaterials also caused a significant increase in lipid 
peroxidation, i.e., enhanced production of 4-HNE, while vitamins attenuated lipid peroxidation 
induced by the osteoblast growth also if cultured in the presence of hydroxyapatite.  
Figure 3. GSH-Px activity in osteoblasts after incubation with hydroxyapatites and treated with
vitamins D3, K1, MK4, and MK7 after 8, 12, 16, and 20 days. The results are expressed as the mU/mg
of protein and are shown as the mean ± SD (n = 5). The values for the control cells and the treated
cells were significantly different according to unpaired Student’s t-test. * Statistically significant
differences versus control, p < 0.05; (a) statistically significant differences versus group hydroxyapatites
(Mx (Maxgraft), Cb (Cerabone), Ap (Apatos), Go (Gen-Os), respectively for graphs (b–e)); p < 0.05.
Furthermore, biomaterials and vitamins affected redox balance in cultured osteoblasts by
modifying lipid metabolism, in the manner similar as observed for ROS levels. Namely, the growth of
osteoblasts was associated with continuous increase of 4-HNE levels (Figure 4). However, different
from the lack of influence of vitamin D3 on the ROS change, the most significant effects on the 4-HNE
production were observed in vitamin D3-treated cultures (Figure 4a), followed by MK-7, with a
reduction of approximately 12–19%. As was noticed in the case of the change of ROS (Figure 1),
the presence of hydroxyapatite biomaterials also caused a significant increase in lipid peroxidation,
i.e., enhanced production of 4-HNE, while vitamins attenuated lipid peroxidation induced by the
osteoblast growth also if cultured in the presence of hydroxyapatite.
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3.2. Osteoblast Growth
Significant increase in the osteoblasts’ DNA levels were observed on day 12 and thereafter,
remaining constant until day 20 (Figure 5). Vitamin D3 did not affect DNA levels, whereas vitamin
K1 accelerated cell proliferation y 12–23%, MK-4 by 15–27%, an MK-7 by 16–51% (Figure 5A).
Addition of vitamin D3 to vitamin K1 and K2 did not chang he rate of osteoblast proliferation.
All hydroxyapatites, with the exception of Maxgraft, inhibited osteoblast proliferation (Figure 5b–e).
The most notable changes were observed for Cerabone, Apatos, and Gen-Os on day 4 and 8 of cu ture,
with a decline in DNA l vels of 23%, 24%, and 37% (day 4), and 12%, 15%, and 36% (day 8), compared
to contr ls. When vitamin D3 was present, oste blast roliferation was not affected. In contrast,
th combinations D3+K1, D3+MK-4, and D3+MK-7 incre sed DNA levels in both controls with no
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hydroxyapatite (10–34%) and osteoblasts cultured in the presence of hydroxyapatite (10–50%); however,
D3+MK-7 was most effective.
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D3, K1, MK4, and MK7 after 4, 8, 12, 16, and 20 days. The results are expressed as the ng/mg of
protein and are shown as the mean ± SD (n = 5). The values for the control cells and the treated cells
were significantly different according to unpaired Student’s t-test. * Statistically significant differences
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Cb (Cerabone), Ap (Apatos), Go (Gen-Os), respectively for graphs (b–e)), p < 0.05;
The osteoblast differentiation process, characterized by increasing ALP activity over time, reached
a maximum after 16 days of culture, and thereafter, began to decrease (Figure 6). Vitamin D3
significantly enhanced ALP activity (40–150%) compared to the control (Figure 6a). Vitamin K1
and K2 did not affect ALP activity; however, the combination of vitamins D3+K1, D3+MK-4,
and D3+MK-7 significantly increased ALP activity. At day 20, the largest increase was observed
in MK-7-treated cultures, with a 2.5-fold increase. The presence of hydroxyapatite-based biomaterials
did not significantly affect ALP activity, with the exception of an increase observed with Maxgraft
(Figure 6b–e). Osteoblasts cultured with hydroxyapatite and treated with vitamin D3 exhibited
significantly higher ALP activity compared to cells grown with only hydroxyapatite and control
(no hydroxyapatite). Moreover, the addition of vitamin D3+K1, D3+MK-4 or D3+MK-7 led to a
significant increase in ALP activity in the presence of hydroxyapatite. The combination of vitamin
Cells 2019, 8, 325 11 of 20
D3 and MK-7 led to the largest increase in ALP activity, particularly evident on day 4 (a two-fold to
four-fold increase).
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D3, K1, MK4, and MK7 after 4, 8, 12, 16, and 20 days. The results are expressed as the nmol/min/mg
of protein and are shown as the mean ± SD (n = 5). The values for the control cells and the treated cells
were significantly different according to unpaired Student’s t-test. * Statistically significant differences
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Cell culture media was collected, and OC levels were estimated as a marker of mineralization.
The OC concentration gradually increased from day 8 to day 20 (Figure 7). Furthermore, synthesis
of OC was enhanced by vitamin D3 treatm nt compared to control (Figure 7a). Vitamin K1 did
not affect OC levels, whereas K2 caused an increase in OC production of 16–18% wi MK-4 and
22–23% with MK-7, t day 16 and 20, respectively. The level of OC also increased in the cell culture
media of D3+K1 (41–66%), D3+MK-4 (47–82%), and D3+MK-7 (55–1 6 ) groups compared to controls.
A decrease in OC concentration (approximately 10–26%) was observed in the media of oste blasts
cultures in the presence of Apatos Gen-Os, resulting in similar OC levels (Figure 7b–e). Vitamin
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D3-treated osteoblasts cultured in the presence of hydroxyapatite had enhanced OC levels compared
to controls and non-treated cells (hydroxyapatite only). Finally, exposing cells to D3+K1, D3+MK-4 or
D3+MK-7 resulted in higher OC levels compared to controls and non-treated cells (hydroxyapatite
only). The greatest enhancements were observed with vitamin D3 (55–120%) and MK-7 (40–120%).
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Figure 7. OC levels in osteoblasts after incubation with hydroxyapatites and treated with vitamins D3,
K1, MK4, and MK7 after 8, 12, 16, and 20 days. The results are expressed as the ng/mL of medium
and are shown as the mean ± SD (n = 5). The values for the control cells and the treated cells were
significantly different according to unpaired Student’s t-test. * Statistically significant differences versus
control, p < 0.05; (a) statistically significant differences versus group hydroxyapatites (Mx (Maxgraft),
Cb (Cerabone), Ap (Apatos), Go (Gen-Os), respectively for graphs (b–e)), p < 0.05. (a) statistically
significant differences versus group vitamin D3 with hydroxyapatites (Mx (Maxgraft), Cb (Cerabone),
Ap (Apatos), Go (Gen-Os), respectively for graphs (b–e)), p < 0.05.
4. Discussion
Hydroxyapatite-based biomaterials are often implanted to support bone regeneration or are
used as a scaffold for culturing osteogenic cells, notably osteoblasts, which are essential for bone
regeneration producing protein and mineral components of bone [50]. During the bone regeneration
process, osteoblasts are recruited to the site of the bone defect, where they proliferate, differentiate,
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and contribute to extracellular matrix mineralization [51]. Biomaterials can cause inflammation and
prolong wound healing as a result of increased ROS generation [52]. Vitamin D3, as well as K1, MK-4,
and MK-7, possess osteoinductive, anti-inflammatory, and antioxidant properties, and may be able to
prevent oxidative stress to improve bone regeneration [18,33,53].
Redox homeostasis results from the balance between ROS generation and the activity of cellular
antioxidants [54]. Under physiological conditions, osteoblasts maintain redox homeostasis; however,
interaction between osteoblasts and biomaterials can disturb this balance leading to oxidative stress.
Results of this study showing that osteoblasts cultured in the presence of xenogeneic and allogeneic
biomaterials exhibit increased ROS generation and reduced antioxidant capacity. Increased ROS
production has been shown to directly affect the biological activity of osteoblasts via inhibition of
Runx2 phosphorylation, the process responsible for transcription of type I collagen, osteopontin,
osteoprotegin, sialoprotein, OC, and ALP [55].
Results of this study indicate that the presence of xenogeneic and allogeneic biomaterials can lead
to antioxidant-related disorders in osteoblasts, including those associated with the GSH-dependent
system. In addition to performing regulatory functions that ensure redox homeostasis, GSH tripeptide
is also a cofactor of glutathione peroxidase, the main enzyme involved in breaking down peroxides
including lipid peroxides. Thus, GSH is responsible for protecting cell membrane phospholipids and
as a consequence, its deficiency can affect the function of biological membranes [56]. Lower GSH
levels prevent glutathione peroxidase from performing its function; therefore, allogeneic biomaterials,
in particular Apatos and Gen-Os, which lower GSH levels, can affect the activity of glutathione
peroxidase, as observed in these studies. As a consequence, the GSH-dependent antioxidant system
cannot properly perform its protective role and increased peroxidation of unsaturated fatty acids
results in the formation of reactive aldehydes, such as 4-HNE, as confirmed by our study. Biomaterials
based on bioactive glass have also been shown to alter the redox homeostasis in osteoblasts’ cells,
manifested as increased 4-HNE production [57]. It should be mentioned that 4-HNE belongs
to the α,β-unsaturated aldehydes, which include carbonyl groups and unsaturated bonds, thus,
rendering them electrophilic and highly biologically reactive compounds mostly targeting nucleophilic
compounds, such as GSH or proteins, leading to a reduction in biological activity including reduced
GSH-Px phosphorylation [58,59]. This is also important because lipid peroxidation products decrease
the expression of genes encoding for bone morphogenetic proteins (BMPs), including BMP2, BMP7,
and BMP4, and therefore inhibit osteoblast maturation [55,60]. On the other hand, 4-HNE is known
to act as growth regulating factor, acting in the concentration dependent and cell-type-specific
manner influencing proliferation, differentiation, and apoptosis [61,62]. Mesenchymal cells, notably
osteoblast-like cells, are especially sensitive to the growth regulating effects of 4-HNE, which interfere
with complex bioactivities of numerous other growth-regulating factors (cytokines, hormones, etc.) and
might eventually be involved in pathophysiology of altered bone growth, as in case of hypertrophic
callus formation or otosclerosis [63,64]. Since 4-HNE was found to be produced by osteoblast-like
cells, the growth of which was enhanced in vitro by bioactive glass, we may assume that production
of 4-HNE by the osteoblasts observed in current study (also in the control cell cultures) supports
previously described growth regulating effects of 4-HNE for the bone cells, while hydroxyapatite
biomaterials resemble effects of bioactive glass [57,65]. However, to maintain functional growth of the
bone cells it is necessary to enhance not only their proliferation but also differentiation, while oxidative
stress and in particular 4-HNE were already proposed to be key mediators that might define the overall
bioactivities of the implantable bioactive materials that require maintenance of the redox balance and
the presence of supportive factors, like cytokines and vitamins [66,67].
Thus, the use of vitamins D3 and K to prevent redox imbalance could be beneficial for the
bone growth and regeneration. Vitamin D3 did not have any effect on ROS level in this study,
whereas ROS levels were significantly decreased with the addition of vitamin K to culture media,
particularly the MK-7 homologue. The mechanism of vitamin K action may be associated with the
inhibition of 12-LOX (lipoxygenase 12) activity [33], which can decrease ROS generation. Moreover,
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inhibiting ROS production may help maintain the metabolic activity of osteoblasts, but at the same
time, could increase osteoclast activity, resulting in increased bone resorption [60]. This could reduce
bone mineral density and the mechanical strength of newly formed and existing bone [68]. Therefore,
vitamin K treatment can have associated consequences including oxidation of reduced glutathione to
glutathione disulphide and reduced GSH-Px activity [69]. This is critical since GSH-Px activity protects
membrane phospholipids and prevents the formation of 4-HNE. At the cellular level, oxidative damage
disturbs cellular metabolism, thereby inhibiting osteoblast proliferation. This could be related to the
oxidative damage to fibronectin, a glycoprotein that regulates certain osteoblast activities including
adhesion, proliferation, migration, and cell morphology [70].
Here, we report decreased GSH levels in osteoblast cultures grown in the presence of allogeneic
and xenogenic bone derivatives and treated with vitamin D3 and/or K. The decrease in GSH levels
was particularly evident in cultures treated with the MK-7 homologue in combination with D3,
which could be related to the vitamin D3-mediated increase in cysteine glutamate ligase (GCLC)
activity which catalysis GSH biosynthesis [71]. Owing to the antioxidant properties of K vitamins,
they can also affect GSH concentration, as confirmed by previous studies on nerve cells [34].
Higher GSH levels are accompanied by elevated GSH-Px activity, which enhances antioxidant activity
in osteoblasts. Cells with enhanced antioxidant activity are less sensitive to oxidative damage and cell
membrane damage.
Our results suggest that vitamin D3 and vitamin K protect osteoblasts from oxidative stress and
have beneficial effects on proliferation, differentiation, and mineralization of osteoblasts cultured both
with and without hydroxyapatite-based biomaterials. This study suggests that vitamin K enhances the
proliferative activity of osteoblasts (measured by DNA concentration). The MK-7 homologue is the
most effective, either alone or combined with vitamin D3. Enhanced proliferation of MK-7-treated
osteoblasts has been confirmed by other authors [72,73]. However, in previous studies, osteoblasts were
not cultured in the presence of hydroxyapatite-based biomaterials. Osteoblast DNA levels have been
associated with OC expression, osteoprotegerin, NFκB ligand (RANKL), and RANK ligand promoter
genes facilitated by vitamin K [74,75]. Furthermore, the vitamin K family participates in sphingolipids
synthesis, in addition to their structural role, sphingolipids take part in proliferation, differentiation,
and intercellular recognition activities of neurons [76]. Vitamin D3 cannot affect proliferation on its
own, but does support osteoblast differentiation, as demonstrated by increased expression of typical
markers such as runt-related transcription factor 2 (RUNX2), type I collagen, alkaline phosphatase,
and OC [77–79]. Our results show that unlike vitamin D3, the K vitamins do not influence osteoblast
differentiation. However, the combination of vitamin K and D3 can significantly enhance osteoblast
differentiation with increasing efficiency: K1 < MK-4 < MK-7. This can clearly be observed when
osteoblasts are cultured in the presence of xenogeneic biomaterials (Maxgraft) and was previously
observed by others [79]. Results of this study confirm previous reports of the participation of vitamin
D3 and K vitamins in the bone regeneration process [75]. Human bone marrow stromal cells (hBMSC)
and 2T3 osteoblast lines treated with vitamin D3 showed a concentration-dependent increase in ALP
activity [80], whereas vitamin K did not affect ALP activity [42].
Osteocalcin is responsible for depositing calcium in bone tissue [81] and both vitamin D3 and
vitamin K participate in the OC biosynthesis and activation processes [82]. In our study, vitamin D3 was
shown to significantly affect OC levels in osteoblasts cultured without hydroxyapatite. A significant
increase in OC synthesis was observed on day 12, indicating the start of the mineralization process.
Other studies have confirmed the influence of vitamin D3 on OC production by osteoblasts [80].
However, we have shown that the presence of biomaterials, in particular, allogeneic bone-derived
biomaterials (Apatos and Gen-Os), significantly decreases OC levels in the medium of osteoblast
cultures. Furthermore, hydroxyapatite has been shown to bind 60–90% of OC [83]. Therefore, observed
differences in the effects of different biomaterials on OC levels may be the result of varying levels of
absorption related to the porosity and composition of the material. The lowest OC levels observed for
osteoblasts cultured in the presence of Gen-Os is most likely owing to the presence of collagen in the
Cells 2019, 8, 325 15 of 20
biomaterial structure. Collagen content favours the absorption of OC since OC binds to the surface of
collagen and further mediates the binding and accumulation of hydroxyapatite crystals on collagen
fibers [40].
The K vitamin family supports biosynthesis of OC by participating in post-translational
carboxylation of Gla residues of OC propeptides [26]. In contrast, carboxylated OC binds calcium to
bone hydroxyapatite, thus supporting bone metabolism [81]. The results of our study indicate the
effects of K vitamins are less significant than those of vitamin D3; however, the combination results in
synergistic effects, even in the presence of allogeneic biomaterials (Apatos and Gen-Os). This could
be because post-translational modification of OC depends on both vitamin D3 and vitamin K [37].
Vitamin D3 activates γ-glutamylcarboxylase for which vitamin K is a cofactor [26,84]. Moreover,
vitamin K intensifies the synthesis and accumulation of carboxylated OC [82], thereby supporting
hydroxyapatite deposition on collagen fibers. This process is regulated by the carboxylated form of
OC [85]. Since vitamins D3 and K have a high affinity for hydroxyapatite, they are absorbed onto
its surface and remain available to cells for a long time, despite the relatively short half-life of both
vitamins [79]. Our results show intensified biosynthesis of OC between day 16 and 20 of the culture.
Clinical studies have also confirmed that vitamin K (MK-4) and vitamin D3 treatments increase bone
mass [86].
5. Conclusions
This study suggests that proliferation and differentiation of human osteoblasts in vitro was
strongly influenced by redox balance, which might be altered in the presence of hydroxyapatite-based
biomaterials. While physiological ROS production-induced lipid peroxidation generating 4-HNE
might be important for the redox homeostasis of the growing osteoblasts, vitamins D3 and/or K
could prevent their excessive production through oxidative stress of the osteoblasts induced by
the biomaterials, thereby preventing their adverse effects on cellular proliferation and osteoblast
differentiation. The most desirable effects on the maintenance of redox homeostasis were in our
in vitro study observed for vitamins D3 and K2, especially the homologue MK-7.
It is suggested that proliferation and differentiation of human osteoblasts in vitro is strongly
influenced by redox balance, which is altered in the presence of hydroxyapatite-based biomaterials.
ROS production and thus induced lipid peroxidation with 4-HNE generation might be important
for the redox homeostasis of the growing osteoblasts, whereas vitamins D3 and/or K could prevent
oxidative stress of the osteoblasts induced by the biomaterials, thereby preventing their adverse effects
on proliferation and osteoblasts differentiation. The most desirable effects were in our in vitro study
observed for vitamins D3 and K2, especially the MK-7 homologue.
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